Gary Mirone, DO
Urogynecology and Reconstructive Pelvic Surgery · Cape May Court House, NJNPI 1972653939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,300 of the $8,791 with a category attached, or 83.0%. Medtronic accounts for 97.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $7,478 and has fallen 98.9% since, to $80 in 2025.
Across 76 payments — averaging $115.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Astellas Pharma US Inc$175
- Boston Scientific$40
Across 1 payment — averaging $252.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$252
What the payments were for
- Speaking & faculty fees$7,30083%
- Food & beverage$1,31615%
- Education$1752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 72 | $8,576 |
| Astellas Pharma US Inc | 2 | $175 |
| Boston Scientific | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$7,300
How this compares
$8,791 in reported general payments places this provider in the 75th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
See all urogynecology and reconstructive pelvic surgery providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 272 | $259,104 |
| GemtesaVibegron | 53 | $62,185 |
| Methenamine Hippurate | 126 | $14,331 |
| Solifenacin Succinate | 197 | $13,344 |
| Mirabegron ErMirabegron | 16 | $11,101 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 235 | $7,169 |
| NitrofurantoinNitrofurantoin Macrocrystal | 78 | $4,260 |
| Estradiol | 67 | $4,117 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,479 |
| Clobetasol Propionate | 20 | $873 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 40 | $704 |
| Cephalexin | 97 | $676 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 31 | $601 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $527 |
| Tamsulosin Hcl | 45 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $175 | $259,104272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
Other urogynecology and reconstructive pelvic surgery in Cape May Court House
- Nina BhatiaManalapan$77K
- Debra FromerHackensack$50K
- Donald DebrakeleerPennington$36K
- Uzma ChaudhryTrenton$14K
- Alexander BergerCherry Hill$14K
- Kristene WhitmoreCherry Hill$13K
- Betsy GreenleafHowell$11K
- Sandy NosseirMarlton$11K
- Anna PancheshnikovVoorhees$8K
- Patricia ZahnerMoorestown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.